Literature DB >> 34023098

PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.

Cecilia Lezcano1, Achim A Jungbluth2, Klaus J Busam2.   

Abstract

PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. Detection of PRAME protein expression by immunohistochemistry in a cohort of 400 melanocytic tumors showed diffuse nuclear immunoreactivity for PRAME in most metastatic and primary melanomas. In contrast, most nevi were negative for PRAME or showed nondiffuse immunoreactivity. The difference in the extent of immunoreactivity for PRAME in unambiguous melanocytic tumors prompted the study of PRAME as an ancillary tool for evaluating melanocytic lesions in more challenging scenarios.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunohistochemistry; Melanoma; Nevus; PReferentially expressed Antigen in MElanoma

Mesh:

Substances:

Year:  2021        PMID: 34023098      PMCID: PMC8152939          DOI: 10.1016/j.path.2021.01.001

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  50 in total

1.  Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma.

Authors:  Pedram Gerami; Susan S Jewell; Larry E Morrison; Beth Blondin; John Schulz; Teresa Ruffalo; Paul Matushek; Mona Legator; Kristine Jacobson; Scott R Dalton; Susan Charzan; Nicholas A Kolaitis; Joan Guitart; Terakeith Lertsbarapa; Susan Boone; Philip E LeBoit; Boris C Bastian
Journal:  Am J Surg Pathol       Date:  2009-08       Impact factor: 6.394

2.  Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.

Authors:  Jessica A Hemminger; Amanda Ewart Toland; Thomas J Scharschmidt; Joel L Mayerson; Denis C Guttridge; O Hans Iwenofu
Journal:  Mod Pathol       Date:  2014-01-24       Impact factor: 7.842

3.  Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization.

Authors:  B C Bastian; P E LeBoit; H Hamm; E B Bröcker; D Pinkel
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

4.  The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.

Authors:  Mirjam T Epping; Liming Wang; Michael J Edel; Leone Carlée; Maria Hernandez; René Bernards
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

5.  Blue naevi of lymph node capsule.

Authors:  J G Azzopardi; C M Ross; G Frizzera
Journal:  Histopathology       Date:  1977-11       Impact factor: 5.087

6.  Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma.

Authors:  David A Biddle; Harry L Evans; Bonnie L Kemp; Adel K El-Naggar; Jeff D Harvell; Wain L White; Sammy S Iskandar; Victor G Prieto
Journal:  Am J Surg Pathol       Date:  2003-05       Impact factor: 6.394

7.  The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.

Authors:  André Oberthuer; Barbara Hero; Rüdiger Spitz; Frank Berthold; Matthias Fischer
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

8.  PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.

Authors:  Matthew G Field; Christina L Decatur; Stefan Kurtenbach; Gülçin Gezgin; Pieter A van der Velden; Martine J Jager; Kaleigh N Kozak; J William Harbour
Journal:  Clin Cancer Res       Date:  2016-03-01       Impact factor: 12.531

9.  Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.

Authors:  Kunio Iura; Kenichi Kohashi; Yuka Hotokebuchi; Takeaki Ishii; Akira Maekawa; Yuichi Yamada; Hidetaka Yamamoto; Yukihide Iwamoto; Yoshinao Oda
Journal:  J Pathol Clin Res       Date:  2015-03-16

10.  PRAME expression and promoter hypomethylation in epithelial ovarian cancer.

Authors:  Wa Zhang; Carter J Barger; Kevin H Eng; David Klinkebiel; Petra A Link; Angela Omilian; Wiam Bshara; Kunle Odunsi; Adam R Karpf
Journal:  Oncotarget       Date:  2016-07-19
View more
  3 in total

1.  Lack of PRAME Expression in Cutaneous T-Cell Lymphomas.

Authors:  Chau M Bui; Sumire Kitahara; Wonwoo Shon; Tatsiana Pukhalskaya; Bruce R Smoller
Journal:  Dermatopathology (Basel)       Date:  2021-12-31

2.  PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples.

Authors:  Andrea Ronchi; Federica Zito Marino; Elvira Moscarella; Gabriella Brancaccio; Giuseppe Argenziano; Teresa Troiani; Stefania Napolitano; Renato Franco; Immacolata Cozzolino
Journal:  Diagnostics (Basel)       Date:  2022-03-06

Review 3.  Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study.

Authors:  Gerardo Cazzato; Katia Mangialardi; Giovanni Falcicchio; Anna Colagrande; Giuseppe Ingravallo; Francesca Arezzo; Giovanna Giliberti; Irma Trilli; Vera Loizzi; Teresa Lettini; Sara Scarcella; Tiziana Annese; Paola Parente; Carmelo Lupo; Nadia Casatta; Eugenio Maiorano; Gennaro Cormio; Leonardo Resta; Domenico Ribatti
Journal:  Genes (Basel)       Date:  2022-03-19       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.